SCHEMBL11323612

SCHEMBL11323612

N/N=C(\N)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.65
MEN1 O00255 1/20 0.65
POLB P06746 2/20 0.54
GRIN2B Q13224 3/20 0.52
GRIN1 Q05586 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
CYP2D6 P10635 1/20 0.48
HIF1A Q16665 1/20 0.48
BLM P54132 2/20 0.48
RECQL P46063 2/20 0.48
CYP2C19 P33261 2/20 0.48
MAPT P10636 2/20 0.48
F2 P00734 1/20 0.48
F10 P00742 1/20 0.48
F12 P00748 1/20 0.48
F7 P08709 1/20 0.48
F3 P13726 1/20 0.48
PKM P14618 1/20 0.48
CYP3A4 P08684 1/20 0.48
PARP1 P09874 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14125504 1.00 KMT2A (0.65) KMT2AMEN1POLBGRIN2BGRIN1
SCHEMBL3828611 1.00 KMT2A (0.65) KMT2AMEN1POLBGRIN2BGRIN1
SCHEMBL19791239 0.80 PRSS1 (0.60) KMT2AMEN1GRIN2BPLAUPRSS1
SCHEMBL18938347 0.80 KMT2A (0.61) KMT2AMEN1POLBGRIN2BGRIN1
SCHEMBL24136574 0.79 KMT2A (1.00) KMT2AMEN1POLBGRIN2BGRIN1
SCHEMBL139363 0.79 KMT2A (1.00) KMT2AMEN1POLBGRIN2BGRIN1
SCHEMBL24662980 0.79 KMT2A (1.00) KMT2AMEN1POLBGRIN2BGRIN1
Benzamidoxime SCHEMBL102483 0.78 KMT2A (0.58) KMT2AMEN1POLBGRIN2BGRIN1
Benzamidoxime SCHEMBL872652 0.78 KMT2A (0.58) KMT2AMEN1POLBGRIN2BGRIN1
SCHEMBL22872296 0.78 KMT2A (0.58) KMT2AMEN1POLBGRIN2BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020122451-A1 COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME 주식회사 엘지화학 2020-06-18 WO disclosed
US-7914908-B2 Organic electroluminescent device having an azatriphenylene derivative GLOBAL OLED TECHNOLOGY LLC (US) 2011-03-29 US disclosed
US-7914908-B2 Organic electroluminescent device having an azatriphenylene derivative GLOBAL OLED TECHNOLOGY LLC (US) 2011-03-29 US disclosed
EP-2280000-A1 COMPOUND HAVING NPY Y5 RECEPTOR ANTAGONIST ACTIVITY Shionogi&Co., Ltd. (JP) 2011-02-02 EP disclosed
US-20090115316-A1 ORGANIC ELECTROLUMINESCENT DEVICE HAVING AN AZATRIPHENYLENE DERIVATIVE GLOBAL OLED TECHNOLOGY LLC 2009-05-07 US disclosed
US-20090115316-A1 ORGANIC ELECTROLUMINESCENT DEVICE HAVING AN AZATRIPHENYLENE DERIVATIVE GLOBAL OLED TECHNOLOGY LLC 2009-05-07 US disclosed
US-4262113-A INTERFACIAL POLYMERIZATION TO FORM HIGH MOLECULAR WEIGHT AROMATIC POLYCARBONATE GENERAL ELECTRIC COMPANY (US) 1981-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090115316-A1 ORGANIC ELECTROLUMINESCENT DEVICE HAVING AN AZATRIPHENYLENE DERIVATIVE DNMT1, EED, ALKBH2 KMT2A 386/4885MEN1 3373/4885POLB 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.